HealthTree recruits over 1,000 participants for study on impact of COVID-19 on MM

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A total of 1,066 patients have joined a HealthTree observational study on COVID-19 and multiple myeloma. All participating patients have filled out a HealthTree profile by contributing their de-identified health data and answered survey questions related to their outcomes during the COVID-19 pandemic.

The aim of the study is to help patients and physicians use real data to drive future medical decisions.

The study was first announced on April 16, 2020. The anonymous answers will be aggregated and analyzed by myeloma researchers to identify recommendations for patients navigating myeloma during the COVID-19 pandemic. Initial study results will be available in July, and more extensive results will be published in December.

Table of Contents

YOU MAY BE INTERESTED IN

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login